var data={"title":"Fluticasone and salmeterol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluticasone and salmeterol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6225?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluticasone-and-salmeterol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluticasone and salmeterol: Patient drug information&quot;</a> and <a href=\"topic.htm?path=fluticasone-and-salmeterol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fluticasone and salmeterol: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50875988\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Long-acting Beta Agonists/Inhaled Corticosteroids Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA has issued a safety alert announcing that, after a review of 4 large clinical trials, treating asthma with a long-acting beta agonist (LABA) in combination with an inhaled corticosteroid (ICS) does not significantly increase serious asthma-related adverse events (asthma-related hospitalizations, need for intubation, or asthma-related deaths) compared to treatment with an ICS alone. In light of these results, the Boxed Warning regarding asthma-related death has been removed from labels of medications containing <i>both</i> an ICS and LABA. Using LABAs without an ICS is associated with an increased risk of asthma-related death; therefore, the Boxed Warnings stating this will remain on labels of all single-ingredient LABA medications.</p>\n        <p style=\"text-indent:0em;\">Healthcare professionals should refer to the most recently approved drug labels for recommendations on using ICS in combination with LABAs. More information may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Drugs/DrugSafety/ucm589587.htm?utm_campaign=New%20FDA%20Drug%20Safety%20Communication%20update%20on%20long-acting%20beta%20agonists%20%28LABAs%29&utm_medium=email&utm_source=Eloqua&amp;token=uo6A9PtUuxWTi4lTE1XNtjZu152WbjMmM807MNFrj/Kg9w2hCrpIoQGgaZO2k23UxW6LecSmEMdKnk21J2TjFGwWde2STooICelklcCGZQb7LJ1ygFuSQvuqFeq+AG1pCrYE7hG+Alb2CaHavRr9IeVqSKmkJT80OO4eqnphQgpSqmG5mBZcKQ3px9yOD1qb8kX4nE7W4r3CCw87KPSyeprfh5O+wjqomRxtEgWubXU=&amp;TOPIC_ID=8730\" target=\"_blank\">https://www.fda.gov/Drugs/DrugSafety/ucm589587.htm?utm_campaign=New%20FDA%20Drug%20Safety%20Communication%20update%20on%20long-acting%20beta%20agonists%20%28LABAs%29&amp;utm_medium=email&amp;utm_source=Eloqua</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173432\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Advair Diskus;</li>\n      <li>Advair HFA;</li>\n      <li>AirDuo RespiClick</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173433\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Advair;</li>\n      <li>Advair Diskus</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173452\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Beta<sub>2</sub> Agonist;</li>\n      <li>\n        Beta<sub>2</sub>-Adrenergic Agonist, Long-Acting;</li>\n      <li>\n        Corticosteroid, Inhalant (Oral)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173436\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Do not use to transfer patients from systemic corticosteroid therapy. Patients receiving fluticasone/salmeterol should not use additional salmeterol or other inhaled, long-acting beta<sub>2</sub>-agonists (eg, formoterol, arformoterol) for any other reason.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma:</b> Inhalation: <b>Note</b>: The recommended starting dose is based upon asthma severity; may increase dose after 2 weeks of therapy in patients who are not adequately controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Advair Diskus: Dry powder inhaler: Initial: 1 inhalation of fluticasone propionate 100 mcg/salmeterol 50 mcg, or fluticasone propionate 250 mcg/salmeterol 50 mcg, or fluticasone propionate 500 mcg/salmeterol 50 mcg twice daily (maximum dose: 1 inhalation of fluticasone propionate 500 mcg/salmeterol 50 mcg twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Advair HFA: Metered dose inhaler: Initial: 2 inhalations of fluticasone propionate 45 mcg/salmeterol 21 mcg, or fluticasone propionate 115 mcg/salmeterol 21 mcg, or fluticasone propionate 230 mcg/salmeterol 21 mcg twice daily (maximum dose: 2 inhalations of fluticasone propionate 230 mcg/salmeterol 21 mcg twice daily).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AirDuo RespiClick: Dry powder inhaler:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">No prior treatment with inhaled corticosteroids: 1 inhalation of fluticasone propionate 55 mcg/salmeterol 14 mcg twice daily (maximum dose: 1 inhalation of fluticasone propionate 232 mcg/salmeterol 14 mcg twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prior treatment with inhaled corticosteroid: 1 inhalation of fluticasone propionate 55 mcg/salmeterol 14 mcg or fluticasone propionate 113 mcg/salmeterol 14 mcg, or fluticasone propionate 232 mcg/salmeterol 14 mcg twice daily (maximum dose: 1 inhalation of fluticasone propionate 232 mcg/salmeterol 14 mcg twice daily).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Advair 125 or Advair 250 [Canadian products]: Dry powder inhaler: Two inhalations twice daily, morning and evening, 12 hours apart</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>COPD:</b> Inhalation: Advair Diskus: Dry powder inhaler: 1 inhalation of fluticasone propionate 250 mcg/salmeterol 50 mcg twice daily (maximum dose: 1 inhalation of fluticasone propionate 250 mcg/salmeterol 50 mcg twice daily)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173446\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=fluticasone-and-salmeterol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Fluticasone and salmeterol: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma:</b> Inhalation: <b>Note</b>: The recommended starting dose is based upon asthma severity; may increase dose after 2 weeks of therapy in patients who are not adequately controlled.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Advair Diskus: Dry powder inhaler:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 11 years of age: One inhalation of fluticasone propionate 100 mcg/salmeterol 50 mcg twice daily (maximum dose: 1 inhalation of fluticasone propionate 100 mcg/salmeterol 50 mcg twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Advair HFA: Metered-dose inhaler: Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AirDuo RespiClick: Dry powder inhaler: Children &ge;12 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173437\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15896264\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173438\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, fluticasone and salmeterol are primarily cleared in the liver and may lead to accumulation in patients with hepatic impairment. Use with caution and monitor closely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173414\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aerosol, for oral inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Advair HFA:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">45/21: Fluticasone propionate 45 mcg and salmeterol 21 mcg per inhalation (8 g, 12 g) [chlorofluorocarbon free]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">115/21: Fluticasone propionate 115 mcg and salmeterol 21 mcg per inhalation (8 g, 12 g) [chlorofluorocarbon free]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">230/21: Fluticasone propionate 230 mcg and salmeterol 21 mcg per inhalation (8 g, 12 g) [chlorofluorocarbon free]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder, for oral inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Advair Diskus:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">100/50: Fluticasone propionate 100 mcg and salmeterol 50 mcg (14s, 60s) [contains lactose]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">250/50: Fluticasone propionate 250 mcg and salmeterol 50 mcg (14s, 60s) [contains lactose]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">500/50: Fluticasone propionate 500 mcg and salmeterol 50 mcg (14s, 60s) [contains lactose]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AirDuo RespiClick:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">55/14: Fluticasone propionate 55 mcg and salmeterol 14 mcg (0.45 g) [contains lactose]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">113/14: Fluticasone propionate 113 mcg and salmeterol 14 mcg (0.45 g) [contains lactose]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">232/14: Fluticasone propionate 232 mcg and salmeterol 14 mcg (0.45 g) [contains lactose]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">55/14: Fluticasone propionate 55 mcg and salmeterol 14 mcg (0.45 g)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">113/14: Fluticasone propionate 113 mcg and salmeterol 14 mcg (0.45 g)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">232/14: Fluticasone propionate 232 mcg and salmeterol 14 mcg (0.45 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173400\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46518245\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Advair HFA 8 g canisters contain 60 inhalations, and the 12 g canisters contain 120 inhalations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AirDuo RespiClick contains 60 inhalations</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6103145\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aerosol, for oral inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Advair;</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">125/25: Fluticasone propionate 125 mcg and salmeterol 25 mcg per inhalation (12 g) [120 metered actuations]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">250/25: Fluticasone propionate 250 mcg and salmeterol 25 mcg per inhalation (12 g) [120 metered actuations]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874505\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Advair Diskus: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm111326.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9UPgXiAK20QB1EgZj8b1kxQaw7NVAjg0dBgxJPo5wF9Q==&amp;TOPIC_ID=8730\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm111326.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Advair HFA: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021254s026lbl.pdf#page=46&amp;token=R25EnBRCQ2dP36ymm4DpDQWDwnuaCh1Y8gqNd/0mxFlCYd/ysRseOFNwbFZG9mtIpzwzJtDq+3Wmpipm8F1LCFdH2fikLbZTLLBygBxjIX1Y/8y01dXGOu9VL8P+5z7O&amp;TOPIC_ID=8730\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021254s026lbl.pdf#page=46</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173417\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Following administration, rinse mouth with water after use (do not swallow) to reduce risk of oral candidiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Advair Diskus: Dry powder inhaler: After removing from box and foil pouch, write the &ldquo;Pouch opened&rdquo; and &ldquo;Use by&rdquo; dates on the label on top of the Diskus. The &ldquo;Use by&rdquo; date is 1 month from date of opening the pouch. Every time the lever is pushed back, a dose is ready to be inhaled. Do not close or tilt the Diskus after the lever is pushed back. Do not play with the lever or move the lever more than once. The dose indicator tells you how many doses are left. When the numbers 5 to 0 appear in red, only a few doses remain. Discard device 1 month after you remove it from the foil pouch or when the dose counter reads &ldquo;0&rdquo; (whichever comes first).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Advair HFA: Metered dose inhaler: Shake well for 5 seconds before each spray. Prime with 4 test sprays (into air and away from face) before using for the first time. If canister is dropped or not used for &gt;4 weeks, prime with 2 sprays. Patient should contact pharmacy for refill when the dose counter reads &ldquo;020&rdquo;. Discard device when the dose counter reads &ldquo;000&rdquo;. Do not spray in eyes.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AirDuo RespiClick: Dry powder inhaler: Inhaler does not require priming and do not use with a spacer or volume holding chamber. Do not wash or place any part of inhaler in water; if mouthpiece needs cleaning, gently wipe with a dry cloth or tissue. When the number 20 appears in red, only a few doses remain. Discard inhaler 30 days after opening the foil pouch or when the counter reads &quot;0&quot;, whichever comes first (device is not reusable).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173416\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Asthma:</b> Treatment of asthma in patients 4 years and older (Advair Diskus) and in patients 12 years and older (Advair HFA, AirDuo RespiClick).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic obstructive pulmonary disease (Advair Diskus only):</b> Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Fluticasone 250 mcg/salmeterol 50 mcg Diskus is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Fluticasone 250 mcg/salmeterol 50 mcg Diskus twice daily is the only approved dosage for the treatment of COPD because an efficacy advantage of the higher strength fluticasone 500 mcg/salmeterol 50 mcg Diskus over fluticasone 250 mcg/salmeterol 50 mcg Diskus has not been demonstrated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Limitations of use: Fluticasone/salmeterol is not indicated for the relief of acute bronchospasm.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173461\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Advair may be confused with Adcirca, Advicor</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173406\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions occur in adults and adolescents unless otherwise specified.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (5% to 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (16% to 27%), pneumonia (4% to 18%; higher incidence is associated with older adults), pharyngitis (&le;13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac arrhythmia (1% to 3%), myocardial infarction (1% to 3%), tachycardia (1% to 3%), palpitations (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Voice disorder (&le;5%), dizziness (&le;4%), migraine (1% to 3%), sleep disorder (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Dermatitis (1% to 3%), dermatologic disease (1% to 3%; includes dermatosis and disorder of sweat and sebum), eczema (1% to 3%), contact dermatitis (&lt;3%), pruritus (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight gain (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Oral candidiasis (1% to 10%; including mouth and throat infections), nausea and vomiting (4% to 6%), nausea (&gt;5%), gastrointestinal distress (&le;4%), viral gastrointestinal infection (3% to 4%), diarrhea (2% to 4%), abdominal distress (1% to 3%), abdominal pain (1% to 3%), dental discomfort (1% to 3%), dental disease (disorder of hard tissue of teeth: 1% to 3%), gastrointestinal infection (1% to 3%), infection of mouth (unspecified oropharyngeal plaque: 1% to 3%), toothache (1% to 3%), xerostomia (1% to 3%), dyspepsia (&lt;3%), upper abdominal pain (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Genitourinary infection (1% to 3%), urinary tract infection (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity reaction (1% to 3%; can be immediate or delayed), local ocular hypersensitivity (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Candidiasis (3%), bacterial infection (1% to 3%), viral infection (1% to 3%), influenza (&lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Musculoskeletal pain (4% to 7%), myalgia (&le;4%), back pain (3%), arthralgia (1% to 3%), arthritis (1% to 3%), muscle injury (1% to 3%), muscle spasm (1% to 3%), ostealgia (1% to 3%), skeletal muscle disease (inflammation: 1% to 3%), skeletal pain (1% to 3%), limb pain (&lt;3%), muscle cramps (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Ocular edema (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Ear sign or symptom (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Throat irritation (8% to 9%; children: &ge;3%), nasopharyngitis (5% to 9%), bronchitis (8%), upper respiratory tract inflammation (4% to 7%; includes upper respiratory tract irritation), cough (4% to 6%), viral respiratory tract infection (4% to 6%), hoarseness (&le;5%), sinusitis (&le;5%), ENT infection (children: &ge;3%), dry nose (1% to 3%), epistaxis (1% to 3%), laryngitis (1% to 3%), lower respiratory signs and symptoms (1% to 3%), lower respiratory tract infection (1% to 3%), postnasal drip (1% to 3%), respiratory tract hemorrhage (lower respiratory tract: 1% to 3%), nasal congestion (&le;3%), allergic rhinitis (&lt;3%), oropharyngeal pain (&lt;3%), respiratory tract infection (&lt;3%), rhinitis (&lt;3%), rhinorrhea (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (4%), inflammation (1% to 3%), laceration (1% to 3%), postoperative complication (1% to 3%), soft tissue injury (1% to 3%), wound (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Hypertonia, mouth pain, nerve compression, pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Exfoliation of skin, ichthyosis, viral skin infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Fluid retention, hyperglycemia, hypothyroidism</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia, oral discomfort, oral lesion, oral mucosa ulcer</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Hematoma, lymphadenopathy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased liver enzymes (incidence may be higher in children but were transient)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Bone fracture, connective tissue disease (cartilage disorder), muscle rigidity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis, eye infection, keratitis, xerophthalmia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasal signs and symptoms, paranasal sinus disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, aggressive behavior, agitation, anaphylaxis, angioedema, anxiety, aphonia, asthma, atrial fibrillation, behavioral changes, bronchospasm (may be immediate), bruise, cataract, chest congestion, chest tightness, choking sensation, cushingoid appearance, Cushing syndrome, decreased linear skeletal growth rate, depression, dysmenorrhea, dyspnea, ecchymoses, esophageal candidiasis, exacerbation of asthma (can be serious), extrasystoles, facial edema, glaucoma, hyperactivity, hypercorticoidism, hypertension, irregular menses, irritability, laryngeal edema, laryngospasm, myositis, oropharyngeal edema, osteoporosis, otalgia, pallor, paradoxical bronchospasm, paresthesia, pelvic inflammatory disease, photodermatitis, restlessness, sinus pain, skin rash, sore throat, stridor, supraventricular tachycardia, syncope, tonsillitis, tracheitis, upper airway swelling, vaginitis, ventricular tachycardia, vulvovaginal candidiasis, vulvovaginitis, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173420\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to fluticasone, salmeterol, or any component of the formulation; status asthmaticus; acute episodes of asthma or COPD; severe hypersensitivity to milk proteins (Advair Diskus, AirDuo RespiClick)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for corticosteroids and sympathomimetics are limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): IgE mediated allergic reactions to lactose; cardiac tachyarrhythmias; untreated fungal, bacterial, or tuberculosis infections of the respiratory tract</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173404\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: Fluticasone may cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis in sensitive patients. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &ge;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do not provide the systemic steroid needed to treat patients having trauma, surgery, or infections. Select surgical patients on long-term, high-dose, inhaled corticosteroid should be given stress doses of hydrocortisone IV during the surgical period and the dose reduced rapidly within 24 hours after surgery (NAEPP 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma-related deaths: The use of long-acting beta-2 agonists (LABAs) as monotherapy is associated with an increased risk of asthma-related deaths. In a large, randomized, placebo-controlled US trial, salmeterol was associated with an increase in asthma-related deaths (SMART 2006); risk is considered a class effect of LABA monotherapy. Additional data from other clinical trials suggests LABA monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. However, data from large randomized, double-blind active-controlled trials do not show a significant increase in the risk of serious asthma-related events (including hospitalizations, intubations, and death) in adult, adolescent, and pediatric (aged 4 to 11 years) patients when fixed-dose LABAs are used with inhaled corticosteroids combined in a single inhaler compared with inhaled corticosteroid monotherapy. In addition, patients receiving fluticasone/salmeterol had fewer severe asthma exacerbations compared with patients receiving fluticasone alone (Peters 2016; Stempel 2016a; Stempel 2016b). Current guidelines recommend the use of an inhaled corticosteroid before adding a LABA (GINA 2015; NIH/NHLBI 2007). Assess patients at regular intervals once asthma control is maintained on combination therapy to determine if step-down therapy is appropriate (without loss of asthma control), and the patient can be maintained on an inhaled corticosteroid only. LABAs are not appropriate in patients whose asthma is adequately controlled on low- or medium-dose inhaled corticosteroids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bronchospasm: Paradoxical bronchospasm that may be life-threatening may occur with use of inhaled bronchodilating agents; reaction should be distinguished from inadequate response. If paradoxical bronchospasm occurs, discontinue fluticasone/salmeterol and institute alternative therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm, hypotension), including anaphylaxis, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Avoid use if possible in patients with ocular herpes; active or quiescent tuberculosis infections of the respiratory tract; or untreated viral, fungal, or bacterial or parasitic systemic infections. Exposure to chickenpox or measles should be avoided; if the patient is exposed, prophylaxis with varicella zoster immune globulin or pooled intramuscular immunoglobulin, respectively, may be indicated; if chickenpox develops, treatment with antiviral agents may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lower respiratory infections: Pneumonia and other lower respiratory tract infections have been reported in patients with COPD following the use of inhaled corticosteroids; monitor COPD patients closely since pneumonia symptoms may overlap symptoms of exacerbations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Oral candidiasis: Local oropharyngeal <i>Candida</i> infections have been reported; if this occurs, treat appropriately while continuing fluticasone therapy. Patients should be instructed to rinse mouth with water without swallowing after each use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serious effects/fatalities: Do not exceed recommended dose or frequency or use with other medications containing LABAs; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Upper airway symptoms: There have been reports of laryngeal spasm, irritation, and swelling (stridor, choking) with use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasculitis: Rare cases of vasculitis (eosinophilic granulomatosis with polyangiitis [formerly known as Churg-Strauss]) or other systemic eosinophilic conditions can occur; often associated with decrease and/or withdrawal of oral corticosteroid therapy following initiation of inhaled corticosteroid.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asthma: Appropriate use: Do <b>not</b> use for acute bronchospasm. Short-acting beta-2 agonist (eg, albuterol) should be used for acute symptoms and symptoms occurring between treatments. Do <b>not</b> initiate in patients with significantly worsening or acutely deteriorating asthma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone mineral density: Use with caution in patients with major risk factors for decreased bone mineral count such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (eg, anticonvulsants or oral corticosteroids); high doses and/or long-term use of inhaled corticosteroids have been associated with decreases in bone mineral density.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia, coronary insufficiency, hypertension, or HF); beta-agonists may cause elevation in blood pressure, heart rate, increase risk of arrhythmia; may also cause ECG changes (eg, flattening of the T wave, QTc prolongation, ST segment depression).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; COPD: Appropriate use: Do <b>not</b> use for acute episodes of COPD. Do <b>not</b> initiate in patients with significantly worsening or acutely deteriorating COPD. Data are not available to determine if LABA use increases the risk of death in patients with COPD.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; beta<sub>2</sub> agonists may increase serum glucose and aggravate preexisting diabetes mellitus and ketoacidosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may lead to accumulation of fluticasone in plasma; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypokalemia: Use with caution in patients with hypokalemia; beta-2 agonists may decrease serum potassium (effect is usually transient).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged fluticasone use. Consider routine eye exams in chronic users.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with seizure disorders; beta-agonists may result in CNS stimulation/excitation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in patients with hyperthyroidism and decreases in hypothyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: LABAs, when used as monotherapy, increase  the risk of asthma-related hospitalization in pediatric and adolescent patients. Orally inhaled and intranasal corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range 0.3 to 1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally inhaled and intranasal corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Powder for oral inhalation (Advair Diskus, AirDuo RespiClick) may contain lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of systemic corticosteroids: Withdraw systemic corticosteroid therapy with gradual tapering of dose; consider reducing the daily prednisone dose by 2.5 to 5 mg on a weekly basis beginning after at least 1 week of inhalation therapy. Monitor lung function, beta-agonist use, asthma symptoms, and for signs and symptoms of adrenal insufficiency (fatigue, lassitude, weakness, nausea and vomiting, hypotension) during withdrawal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Patient information: Patients must be instructed to use short-acting beta-2 agonist (eg, albuterol) for acute asthmatic or COPD symptoms and to seek medical attention in cases where acute symptoms are not relieved or a previous level of response is diminished. The need to increase frequency of use of inhaled short-acting beta-2 agonist may indicate deterioration of asthma, and medical evaluation must not be delayed. Therapy should not be used more than twice daily; do not use with other long-acting beta-2 agonists.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173447\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual components.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173408\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8730&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists (Long-Acting): May enhance the adverse/toxic effect of other Beta2-Agonists (Long-Acting).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betahistine: May diminish the therapeutic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Fluticasone (Oral Inhalation).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Salmeterol.<b> Exceptions: </b>Grapefruit Juice.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Salmeterol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Corticosteroids (Orally Inhaled) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Salmeterol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Salmeterol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Fluticasone (Oral Inhalation).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173424\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies using this combination. Refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20472559\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if fluticasone or salmeterol are present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Refer to individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173425\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Advair Diskus powder for oral inhalation contains lactose; very rare anaphylactic reactions have been reported in patients with severe milk protein allergy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173412\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">FEV<sub>1</sub>, peak flow, and/or other pulmonary function tests; blood pressure, heart rate; CNS stimulation; glaucoma and cataracts; bone mineral density (baseline and periodically thereafter); serum potassium (hypokalemic patients); glucose (diabetic patients); glaucoma/cataracts; signs/symptoms of oral candidiasis; signs/symptoms of HPA axis suppression/adrenal insufficiency; growth (adolescents and children via stadiometry).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173403\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Combination of fluticasone (corticosteroid) and salmeterol (long-acting beta<sub>2</sub>-agonist) designed to improve pulmonary function and control over what is produced by either agent when used alone. Because fluticasone and salmeterol act locally in the lung, plasma levels do not predict therapeutic effect. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Fluticasone: The mechanism of action for all topical corticosteroids is believed to be a combination of three important properties: Anti-inflammatory activity, immunosuppressive properties, and antiproliferative actions. Fluticasone has extremely potent vasoconstrictive and anti-inflammatory activity. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Salmeterol: Relaxes bronchial smooth muscle by selective action on beta<sub>2</sub>-receptors with little effect on heart rate</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173419\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">See individual agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173423\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol</b> (Advair HFA Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45-21 mcg/ACT (8 g): $254.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">115-21 mcg/ACT (8 g): $254.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">230-21 mcg/ACT (8 g): $378.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (Advair Diskus Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100-50 mcg/dose (14): $182.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250-50 mcg/dose (14): $182.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500-50 mcg/dose (14): $296.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (AirDuo RespiClick 113/14 Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">113-14 mcg/ACT (1): $362.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (AirDuo RespiClick 232/14 Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">232-14 mcg/ACT (1): $362.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (AirDuo RespiClick 55/14 Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">55-14 mcg/ACT (1): $362.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Aerosol powder</b> (Fluticasone-Salmeterol Inhalation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">55-14 mcg/ACT (1): $119.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">113-14 mcg/ACT (1): $119.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">232-14 mcg/ACT (1): $119.25</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F173426\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adeflo (PH);</li>\n      <li>Adomir (JP);</li>\n      <li>Advair (BM);</li>\n      <li>Aeronid (PE);</li>\n      <li>Airflusal Forspiro (KR, PH, VN);</li>\n      <li>Aroflo (BD);</li>\n      <li>Combiwave SF (MY, PH, VN);</li>\n      <li>Fluamar (CO);</li>\n      <li>Flutias (ID);</li>\n      <li>Flutizal (PH);</li>\n      <li>Forair (PH);</li>\n      <li>Kovent SF (PH);</li>\n      <li>Salflu (BD);</li>\n      <li>Salflu MDI (BD);</li>\n      <li>Salmed (PH);</li>\n      <li>Salmeflo (PH);</li>\n      <li>Seretaide (PT);</li>\n      <li>Seretide (AR, AT, BB, BE, BG, BM, BR, BS, BZ, CH, CL, CN, CO, CR, CZ, DK, DO, EC, EE, ES, FI, FR, GB, GT, GY, HK, HN, HR, ID, IE, IL, IN, IS, IT, JM, KR, LT, LU, LV, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PY, RO, SE, SG, SI, SK, SR, SV, TH, TT, TW, VE, VN, ZW);</li>\n      <li>Seretide Accuhaler (AU);</li>\n      <li>Seretide Diskus (AE, CY, JO, KW, LB, QA, SA);</li>\n      <li>Seretide Evohaler (BH, JO, LK);</li>\n      <li>SeretideDiskus (BH);</li>\n      <li>Serflu (UY);</li>\n      <li>Seroflo (HK);</li>\n      <li>Seroxyn (BD);</li>\n      <li>Sirdupla (GB);</li>\n      <li>Viani (DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Advair (fluticasone/salmeterol) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; May 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Advair Diskus (fluticasone/salmeterol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Advair Diskus (fluticasone/salmeterol) [product monograph]. Mississauga, Ontario: GlaxoSmithKline Inc; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Advair HFA (fluticasone/salmeterol) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    AirDuo RespiClick (fluticasone/salmeterol) [prescribing information]. Frazer, PA: Teva Respiratory, LLC; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo; <i>J Am Coll Cardiol</i>, 2007, 50(7):e1-157.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-and-salmeterol-drug-information/abstract-text/17692738/pubmed\" target=\"_blank\" id=\"17692738\">17692738</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bateman ED, Boushey HA, Bousquet J, et al, &ldquo;Can Guideline-Defined Asthma Control Be Achieved? The Gaining Optimal Asthma Control Study,&rdquo; <i>Am J Respir Crit Care Med</i>, 2004, 170(8):836-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-and-salmeterol-drug-information/abstract-text/15256389/pubmed\" target=\"_blank\" id=\"15256389\">15256389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Castle W, Fuller R, Hall J, et al, &ldquo;Serevent Nationwide Surveillance Study: Comparison of Salmeterol With Salbutamol in Asthmatic Patients Who Require Regular Bronchodilator Treatment,&rdquo; <i>BMJ</i>, 1993, 306(6884):1034-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-and-salmeterol-drug-information/abstract-text/8098238/pubmed\" target=\"_blank\" id=\"8098238\">8098238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2015. www.ginasthma.org. Updated 2015. Accessed June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. <i>Expert Panel on the Management of Asthma. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007</i>. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. <a href=\"http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. <i>Chest</i>. 2006;129(1):15-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-and-salmeterol-drug-information/abstract-text/16424409/pubmed\" target=\"_blank\" id=\"16424409\">16424409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peters SP, Bleecker ER, Canonica GW, et al. Serious asthma events with budesonide plus formoterol vs. budesonide alone. <i>N Engl J Med.</i> 2016;375(9):850-860. doi: 10.1056/NEJMoa1511190.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-and-salmeterol-drug-information/abstract-text/27579635/pubmed\" target=\"_blank\" id=\"27579635\">27579635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stempel DA, Raphiou IH, Kral KM, et al; AUSTRI Investigators. Serious asthma events with fluticasone plus salmeterol versus fluticasone alone. <i>N Engl J Med</i>. 2016a;374(19):1822-1830. doi: 10.1056/NEJMoa1511049.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-and-salmeterol-drug-information/abstract-text/26949137/pubmed\" target=\"_blank\" id=\"26949137\">26949137</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stempel DA, Szefler SJ, Pedersen S, et al; VESTRI Investigators. Safety of adding salmeterol to fluticasone propionate in children with asthma. <i>N Engl J Med.</i> 2016b;375(9):840-849. doi: 10.1056/NEJMoa1606356.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluticasone-and-salmeterol-drug-information/abstract-text/27579634/pubmed\" target=\"_blank\" id=\"27579634\">27579634</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007. <a href=\"http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf\" target=\"_blank\">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</a>. Published August 28, 2007.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8730 Version 180.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50875988\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F173432\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F173433\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F173452\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F173436\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F173446\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F173437\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15896264\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F173438\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F173414\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F173400\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F46518245\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F6103145\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874505\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F173417\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F173416\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F173461\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F173406\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F173420\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F173404\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F173447\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F173408\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F173424\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20472559\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F173425\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F173412\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F173403\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F173419\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F173423\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F173426\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8730|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluticasone-and-salmeterol-patient-drug-information\" class=\"drug drug_patient\">Fluticasone and salmeterol: Patient drug information</a></li><li><a href=\"topic.htm?path=fluticasone-and-salmeterol-pediatric-drug-information\" class=\"drug drug_pediatric\">Fluticasone and salmeterol: Pediatric drug information</a></li></ul></div></div>","javascript":null}